Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 9.05
PRTA's Cash-to-Debt is ranked lower than
56% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. PRTA: 9.05 )
Ranked among companies with meaningful Cash-to-Debt only.
PRTA' s Cash-to-Debt Range Over the Past 10 Years
Min: 7.54  Med: No Debt Max: No Debt
Current: 9.05
Equity-to-Asset 0.84
PRTA's Equity-to-Asset is ranked higher than
74% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. PRTA: 0.84 )
Ranked among companies with meaningful Equity-to-Asset only.
PRTA' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.79  Med: 0.95 Max: 0.98
Current: 0.84
0.79
0.98
Debt-to-Equity 0.11
PRTA's Debt-to-Equity is ranked higher than
72% of the 461 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. PRTA: 0.11 )
Ranked among companies with meaningful Debt-to-Equity only.
PRTA' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.08  Med: 0.1 Max: 0.14
Current: 0.11
0.08
0.14
Piotroski F-Score: 2
Altman Z-Score: 15.52
Beneish M-Score: 17.82
WACC vs ROIC
20.41%
-371.19%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -531.71
PRTA's Operating Margin % is ranked lower than
94% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. PRTA: -531.71 )
Ranked among companies with meaningful Operating Margin % only.
PRTA' s Operating Margin % Range Over the Past 10 Years
Min: -15121.8  Med: -4974.3 Max: -13.07
Current: -531.71
-15121.8
-13.07
Net Margin % -527.56
PRTA's Net Margin % is ranked lower than
94% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. PRTA: -527.56 )
Ranked among companies with meaningful Net Margin % only.
PRTA' s Net Margin % Range Over the Past 10 Years
Min: -15176.11  Med: -5016.3 Max: -14.06
Current: -527.56
-15176.11
-14.06
ROE % -33.30
PRTA's ROE % is ranked lower than
51% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. PRTA: -33.30 )
Ranked among companies with meaningful ROE % only.
PRTA' s ROE % Range Over the Past 10 Years
Min: -68.99  Med: -27.35 Max: -3.09
Current: -33.3
-68.99
-3.09
ROA % -27.90
PRTA's ROA % is ranked lower than
52% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. PRTA: -27.90 )
Ranked among companies with meaningful ROA % only.
PRTA' s ROA % Range Over the Past 10 Years
Min: -1640.13  Med: -32.1 Max: -2.94
Current: -27.9
-1640.13
-2.94
ROC (Joel Greenblatt) % -278.83
PRTA's ROC (Joel Greenblatt) % is ranked lower than
51% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. PRTA: -278.83 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PRTA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2303.58  Med: -1285.66 Max: -204.81
Current: -278.83
-2303.58
-204.81
3-Year Revenue Growth Rate -4.90
PRTA's 3-Year Revenue Growth Rate is ranked lower than
63% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. PRTA: -4.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PRTA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -33.7  Med: -15.05 Max: 289
Current: -4.9
-33.7
289
3-Year EBITDA Growth Rate 28.90
PRTA's 3-Year EBITDA Growth Rate is ranked higher than
81% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. PRTA: 28.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PRTA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -50.7  Med: 13.25 Max: 37.3
Current: 28.9
-50.7
37.3
3-Year EPS without NRI Growth Rate 28.40
PRTA's 3-Year EPS without NRI Growth Rate is ranked higher than
82% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. PRTA: 28.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PRTA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -47.9  Med: 13.1 Max: 36.8
Current: 28.4
-47.9
36.8
GuruFocus has detected 5 Warning Signs with Prothena Corp PLC $PRTA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PRTA's 30-Y Financials

Financials (Next Earnings Date: 2017-11-01 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

PRTA Guru Trades in Q3 2016

Vanguard Health Care Fund 2,150,294 sh (unchged)
Pioneer Investments 119,324 sh (-0.53%)
Ken Fisher 13,856 sh (-27.23%)
» More
Q4 2016

PRTA Guru Trades in Q4 2016

Vanguard Health Care Fund 2,150,294 sh (unchged)
Pioneer Investments 116,424 sh (-2.43%)
Ken Fisher 10,718 sh (-22.65%)
» More
Q1 2017

PRTA Guru Trades in Q1 2017

Paul Tudor Jones 38,008 sh (New)
Ken Fisher 13,503 sh (+25.98%)
Vanguard Health Care Fund 2,150,294 sh (unchged)
Pioneer Investments 115,932 sh (-0.42%)
» More
Q2 2017

PRTA Guru Trades in Q2 2017

Ken Fisher 21,822 sh (+61.61%)
Vanguard Health Care Fund 2,150,294 sh (unchged)
Paul Tudor Jones Sold Out
Pioneer Investments 58,044 sh (-49.93%)
» More
» Details

Insider Trades

Latest Guru Trades with PRTA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2017-06-30 Add 61.61%$49 - $58.73 $ 64.6221%21,822
Ken Fisher 2017-03-31 Add 25.98%$46.37 - $60.33 $ 64.6223%13,503
Ken Fisher 2016-12-31 Reduce -22.65%$40.72 - $67.64 $ 64.6217%10,718
Ken Fisher 2016-09-30 Reduce -27.23%$38.45 - $63.6 $ 64.6220%13,856
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:AMRN, NAS:AVDL, NAS:NBRV, NAS:NVET, NAS:ALKS, NAS:JAZZ, LSE:SHP » details
Traded in other countries:0PT.Germany,
Headquarter Location:Ireland
Prothena Corp PLC is a biotechnology company. It discovers and develops novel antibodies for the potential treatment of a broad range of diseases that involve protein misfolding or cell adhesion.

Prothena Corporation PLC was incorporated in Ireland as a private limited company under the name Neotope Corporation Limited on September 26, 2012. On November1, 2012, it changed the name of the company to Prothena Corporation plc. It is a biotechnology company engaged in the discovery and development of novel antibodies for the potential treatment of an array of diseases that involve protein misfolding or cell adhesion. Its research and development pipeline includes three main therapeutic antibody programs: NEOD001 for the treatment of AL and AA Amyloidosis; PRX002 (formerly NEOD002) for the treatment of Parkinson's disease; and PRX003 for the potential treatment of inflammatory disease and metastatic cancers. Its pipeline also includes two late discovery stage programs: tau antibodies for potential treatment of Alzheimer's disease and antibodies for the potential treatment of type 2 diabetes. The competitors consist of major international companies, all of which are larger and have greater financial resources, technical staff, manufacturing, R&D and marketing capabilities. It also competes with smaller research companies and generic drug and biosimilar manufacturers. It is subject to significant regulation by international, national, state and local governmental regulatory agencies.

Ratios

vs
industry
vs
history
PB Ratio 5.13
PRTA's PB Ratio is ranked lower than
51% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. PRTA: 5.13 )
Ranked among companies with meaningful PB Ratio only.
PRTA' s PB Ratio Range Over the Past 10 Years
Min: 0.84  Med: 3.57 Max: 6.28
Current: 5.13
0.84
6.28
PS Ratio 89.26
PRTA's PS Ratio is ranked lower than
97% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. PRTA: 89.26 )
Ranked among companies with meaningful PS Ratio only.
PRTA' s PS Ratio Range Over the Past 10 Years
Min: 8.28  Med: 306.18 Max: 1915
Current: 89.26
8.28
1915
EV-to-EBIT -14.04
PRTA's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. PRTA: -14.04 )
Ranked among companies with meaningful EV-to-EBIT only.
PRTA' s EV-to-EBIT Range Over the Past 10 Years
Min: -348.9  Med: -12 Max: 0.9
Current: -14.04
-348.9
0.9
EV-to-EBITDA -14.38
PRTA's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. PRTA: -14.38 )
Ranked among companies with meaningful EV-to-EBITDA only.
PRTA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -103.1  Med: -11.05 Max: 4476
Current: -14.38
-103.1
4476
EV-to-Revenue 74.63
PRTA's EV-to-Revenue is ranked lower than
96% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. PRTA: 74.63 )
Ranked among companies with meaningful EV-to-Revenue only.
PRTA' s EV-to-Revenue Range Over the Past 10 Years
Min: -13.3  Med: 248 Max: 1555.4
Current: 74.63
-13.3
1555.4
Current Ratio 12.92
PRTA's Current Ratio is ranked higher than
90% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. PRTA: 12.92 )
Ranked among companies with meaningful Current Ratio only.
PRTA' s Current Ratio Range Over the Past 10 Years
Min: 0.01  Med: 20.98 Max: 72.16
Current: 12.92
0.01
72.16
Quick Ratio 12.92
PRTA's Quick Ratio is ranked higher than
90% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. PRTA: 12.92 )
Ranked among companies with meaningful Quick Ratio only.
PRTA' s Quick Ratio Range Over the Past 10 Years
Min: 0.01  Med: 20.98 Max: 72.16
Current: 12.92
0.01
72.16
Days Sales Outstanding 400.96
PRTA's Days Sales Outstanding is ranked lower than
67% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. PRTA: 400.96 )
Ranked among companies with meaningful Days Sales Outstanding only.
PRTA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 12.41  Med: 31.32 Max: 400.96
Current: 400.96
12.41
400.96

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -16.40
PRTA's 3-Year Average Share Buyback Ratio is ranked lower than
63% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. PRTA: -16.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PRTA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -23.6  Med: -18.95 Max: -14.7
Current: -16.4
-23.6
-14.7

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 6.52
PRTA's Price-to-Net-Cash is ranked higher than
65% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. PRTA: 6.52 )
Ranked among companies with meaningful Price-to-Net-Cash only.
PRTA' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.05  Med: 3.86 Max: 6.59
Current: 6.52
1.05
6.59
Price-to-Net-Current-Asset-Value 5.90
PRTA's Price-to-Net-Current-Asset-Value is ranked higher than
64% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. PRTA: 5.90 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
PRTA' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.03  Med: 3.82 Max: 6.13
Current: 5.9
1.03
6.13
Price-to-Tangible-Book 5.08
PRTA's Price-to-Tangible-Book is ranked higher than
56% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. PRTA: 5.08 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
PRTA' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1  Med: 3.62 Max: 5.99
Current: 5.08
1
5.99
Price-to-Median-PS-Value 0.29
PRTA's Price-to-Median-PS-Value is ranked lower than
94% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. PRTA: 0.29 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PRTA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.03  Med: 0.96 Max: 6.03
Current: 0.29
0.03
6.03
Earnings Yield (Greenblatt) % -7.13
PRTA's Earnings Yield (Greenblatt) % is ranked lower than
57% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. PRTA: -7.13 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PRTA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -205.9  Med: -7.6 Max: 74709.2
Current: -7.13
-205.9
74709.2

More Statistics

Revenue (TTM) (Mil) $27.53
EPS (TTM) $ -4.12
Beta3.31
Short Percentage of Float30.67%
52-Week Range $40.58 - 69.53
Shares Outstanding (Mil)38.28

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 19 35 92
EPS ($) -3.30 -4.09 -2.53
EPS without NRI ($) -3.30 -4.09 -2.53
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for PRTA

Headlines

Articles On GuruFocus.com
Prothena Presents New Research Supporting Clinical Relevance of Cardiac Biomarker NT-proBNP in AL Sep 18 2017 
Prothena to Present New Research on Cardiac Biomarker NT-proBNP in AL Amyloidosis at HFSA Annual Mee Aug 15 2017 
Prothena Reports Second Quarter 2017 Financial Results and Provides R&D Update Aug 08 2017 
Prothena to Report Second Quarter 2017 Financial Results on August 8 Aug 01 2017 
Prothena Announces Appointment of Wagner Zago, PhD as Chief Scientific Officer Jun 12 2017 
Prothena Announces Appointment of Sarah Noonberg, MD, PhD as Chief Medical Officer May 16 2017 
Prothena Reports First Quarter 2017 Financial Results and Provides R&D Update May 09 2017 
Prothena to Report First Quarter 2017 Financial Results on May 9 May 02 2017 
Prothena to Participate in the Deutsche Bank 42nd Annual Health Care Conference Apr 26 2017 
Clinical Results Presented from Prothena’s Phase 1b Study of PRX002/RG7935 Demonstrating Robust Apr 02 2017 

More From Other Websites
Prothena Presents New Research Supporting Clinical Relevance of Cardiac Biomarker NT-proBNP in AL... Sep 18 2017
Stocks Flashing Renewed Technical Strength: Prothena Sep 18 2017
ETFs with exposure to Prothena Corp. Plc : September 13, 2017 Sep 13 2017
Prothena Corp. Plc :PRTA-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017 Sep 11 2017
Prothena Corp. Plc breached its 50 day moving average in a Bullish Manner : PRTA-US : September 1,... Sep 01 2017
AstraZeneca and Takeda Ink Deal to Develop Parkinson's Drug Aug 30 2017
Prothena Corp. Plc – Value Analysis (NASDAQ:PRTA) : August 23, 2017 Aug 23 2017
Prothena to Present New Research on Cardiac Biomarker NT-proBNP in AL Amyloidosis at HFSA Annual... Aug 15 2017
Prothena Corp. Plc breached its 50 day moving average in a Bearish Manner : PRTA-US : August 11,... Aug 11 2017
Prothena (PRTA) Q2 Loss Narrows as Roche Makes $30M Payment Aug 09 2017
Prothena reports 2Q loss Aug 08 2017
Prothena Reports Second Quarter 2017 Financial Results and Provides R&D Update Aug 08 2017
Should You Buy Prothena Corporation PLC (PRTA) Ahead of Earnings? Aug 07 2017
Prothena to Report Second Quarter 2017 Financial Results on August 8 Aug 01 2017
Can Prothena (PRTA) Deliver a Beat this Earnings Season? Jul 28 2017
Prothena Announces Initiation of Phase 2 PASADENA Study of PRX002/RG7935 in Patients with Early... Jul 05 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}